A Study shows mutation-resistant antibodies with 269×affinity, a proof point for CEPI’s 100 Days Mission and closing ...

Human MAP1LC3B (LC3B) binds proteins involved in autophagy and other cellular processes using a degenerate four-residue short linear motif known as the LC3-interacting region (LIR). Biochemical and ...

With the widespread use of pesticides in modern agriculture, issues such as food contamination, ecological damage, and public ...

Isomorphic Lab’s proprietary drug-discovery model is a major advance, but scientists developing open-source tools are left ...

Artificial intelligence has moved from pilot projects to a central role in many life sciences strategies. What began as a set ...

JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over ...

Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings ...

Sagar Lonial, MD, discusses the evolving role of cereblon E3 ligase modulators (CELMoDs) in the treatment of multiple myeloma. In an interview with Targeted Oncology, Sagar Lonial, MD, Professor and ...

Creative Biolabs announces upgraded downstream services designed to bridge the gap between raw antibody expression and ...

The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future. Recently, the U.S. Food and Drug Administration (FDA) accepted a new drug ...

CEO Martin Lehr outlined the company’s strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare ...